Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib vs continued second-line/third-line TKI in CML-CP patients without MMR
ChiCTR2300072680Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of olverembatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Major molecular response rate at 6 months after treatment switch or continuation. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
olverembatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR2300072680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072680.